Palatin Technologies (PTN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for July 25, 2025, to be held virtually, with voting on key corporate matters and director elections.
Board recommends voting in favor of all director nominees and all major proposals, including a reverse stock split, auditor ratification, warrant share issuances, equity plan amendment, and executive compensation matters.
Proxy materials distributed to all shareholders, with detailed instructions for virtual participation and voting.
Voting matters and shareholder proposals
Election of four directors to serve until the next annual meeting.
Approval of a reverse stock split at a ratio between 1-for-50 and 1-for-100, at the board's discretion.
Ratification of KPMG LLP as independent auditor for fiscal year ending June 30, 2025.
Approval of share issuances upon exercise of Series B, D, and I warrants, with potential dilution effects.
Amendment to increase shares available under the 2011 Stock Incentive Plan by 3,000,000 shares.
Advisory votes on the frequency (recommended annually) and approval of executive compensation.
Procedures for shareholder proposals and director nominations for the next annual meeting outlined.
Board of directors and corporate governance
Four director nominees, three of whom are independent, with diverse industry and leadership experience.
Board committees include audit, compensation, and nominating/governance, all with independent members.
Annual performance evaluations and a focus on diversity in board composition.
Board leadership structure separates CEO and Chairman roles.
Code of conduct and ethics applies to all directors, officers, and employees.
Latest events from Palatin Technologies
- MC4R-based obesity pipeline advances with strong cash reserves and clinical trials set for 2026.PTN
Q2 202627 Feb 2026 - Advancing MC4R agonists for rare obesity and forging key partnerships for future growth.PTN
Corporate presentation17 Feb 2026 - Net loss of $29.7M, asset sale, and pipeline progress set stage for key 2024–2025 milestones.PTN
Q4 202419 Jan 2026 - No product revenue, $7.8M net loss, and a strategic pivot to obesity programs with key data due in 2025.PTN
Q1 202514 Jan 2026 - Net loss narrowed, no product revenue, and liquidity risks persist amid advancing clinical programs.PTN
Q2 202524 Dec 2025 - Shareholders to vote on director elections, reverse split, warrants, and equity plan changes.PTN
Proxy Filing1 Dec 2025 - Highly dilutive best-efforts offering seeks urgent capital to fund clinical programs and avoid delisting.PTN
Registration Filing29 Nov 2025 - Biopharma firm seeks up to $9.1M from warrant exercises amid financial and listing challenges.PTN
Registration Filing29 Nov 2025 - No new securities registered; amendment provides auditor consent and details recent capital raises.PTN
Registration Filing29 Nov 2025